Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib + TCS in cyclosporine-resistant atopic dermatitis
NCT03428100Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2018
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 14
01
Overview
A Phase 3 trial of baricitinib in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Started May 2018; status: completed.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03428100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03428100.